<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7410019\results\search\drug\results.xml">
  <result pre="higher risk of infection. Based on these considerations, we suggest" exact="ibrutinib" post="or acalabrutinib and, for logistical reasons, venetoclax for patients"/>
  <result pre="of infection. Based on these considerations, we suggest ibrutinib or" exact="acalabrutinib" post="and, for logistical reasons, venetoclax for patients not fitting"/>
  <result pre="considerations, we suggest ibrutinib or acalabrutinib and, for logistical reasons," exact="venetoclax" post="for patients not fitting for BTK inhibitors. We use"/>
  <result pre="or obinutuzumab combinations and delay combining anti-CD20 monoclonal antibodies with" exact="venetoclax" post="until later in the course of treatment when safer."/>
  <result pre="in the course of treatment when safer. Ibrutinib, acalabrutinib, and" exact="venetoclax" post="prolong progression-free and overall survival with lower risk of"/>
  <result pre="compared to chemo(immuno)therapy.43â€&quot;46,54,56,58,59 The percentage of opportunistic infections reported for" exact="ibrutinib" post="is low (4.1%) and similar to that reported for"/>
  <result pre="ibrutinib is low (4.1%) and similar to that reported for" exact="venetoclax" post="(3.1%).79â€&quot;82 Compared to chemo(immuno)therapy, ibrutinib and acalabrutinib do not"/>
  <result pre="similar to that reported for venetoclax (3.1%).79â€&quot;82 Compared to chemo(immuno)therapy," exact="ibrutinib" post="and acalabrutinib do not produce lymphopenia, a known risk"/>
  <result pre="that reported for venetoclax (3.1%).79â€&quot;82 Compared to chemo(immuno)therapy, ibrutinib and" exact="acalabrutinib" post="do not produce lymphopenia, a known risk factor for"/>
  <result pre="of any â‰¥3 grade adverse events does not differ between" exact="ibrutinib" post="(41%â€&quot;77%), acalabrutinib (50%), and venetoclax (78%), indicating that the"/>
  <result pre="â‰¥3 grade adverse events does not differ between ibrutinib (41%â€&quot;77%)," exact="acalabrutinib" post="(50%), and venetoclax (78%), indicating that the frequency of"/>
  <result pre="events does not differ between ibrutinib (41%â€&quot;77%), acalabrutinib (50%), and" exact="venetoclax" post="(78%), indicating that the frequency of unplanned visits for"/>
  <result pre="visits for tumor lysis management during the ramp up phase." exact="Ibrutinib" post="treatment requires few routine treatment visits and lab assessments.54"/>
  <result pre="a few reports from uncontrolled clinical cases.86,87 The disadvantage of" exact="ibrutinib" post="treatment during SARS-CoV-2 outbreak is the continuous schedule not"/>
  <result pre="the continuous schedule not allowing treatment free intervals. However, if" exact="ibrutinib" post="is discontinued because of an adverse event while CLL"/>
  <result pre="to normal levels within an average of 60 days from" exact="venetoclax" post="discontinuation.83,91 The disadvantage of venetoclax treatment is the need"/>
  <result pre="average of 60 days from venetoclax discontinuation.83,91 The disadvantage of" exact="venetoclax" post="treatment is the need for frequent access to the"/>
  <result pre="ramp-up phase to prevent tumor lysis syndrome (TLS).58 In addition," exact="venetoclax" post="treatment has a relatively high risk of neutropenia during"/>
  <result pre="higher drug discontinuation rate due to adverse events compared to" exact="acalabrutinib" post="treated patients.59 Treatment with rituximab or obinutuzumab produces a"/>
  <result pre="do not apply prophylactic interruption or dose reductions of ibrutinib," exact="acalabrutinib" post="or venetoclax based on the reasoning that once treatment"/>
  <result pre="apply prophylactic interruption or dose reductions of ibrutinib, acalabrutinib or" exact="venetoclax" post="based on the reasoning that once treatment has started,"/>
  <result pre="maximum benefit. This is illustrated by the evidence that temporary" exact="ibrutinib" post="dose interruptions associate with shorter progression free survival, suggesting"/>
  <result pre="phase III study. J Clin Oncol.2019;37:269â€&quot;277.30523712 47.BurgerJASivinaMJainNet al.Randomized trial of" exact="ibrutinib" post="vs ibrutinib plus rituximab in patients with chronic lymphocytic"/>
  <result pre="study. J Clin Oncol.2019;37:269â€&quot;277.30523712 47.BurgerJASivinaMJainNet al.Randomized trial of ibrutinib vs" exact="ibrutinib" post="plus rituximab in patients with chronic lymphocytic leukemia. Blood.2019;133:1011â€&quot;1019.30530801"/>
  <result pre="in patients with chronic lymphocytic leukemia. Blood.2019;133:1011â€&quot;1019.30530801 48.RobertsAWMaSKippsTJet al.Efficacy of" exact="venetoclax" post="in relapsed chronic lymphocytic leukemia is influenced by disease"/>
  <result pre="49.ByrdJCHillmenPOâ€™BrienSet al.Long-term follow-up of the RESONATE phase 3 trial of" exact="ibrutinib" post="vs ofatumumab. Blood.2019;133:2031â€&quot;2042.30842083 50.ByrdJCFurmanRRCoutreSEet al.Ibrutinib treatment for first-line and"/>
  <result pre="study in patients with previously treated CLL/SLL. Leukemia.2018;32:83â€&quot;91.28592889 52.Oâ€™BrienSFurmanRRCoutreSet al.Single-agent" exact="ibrutinib" post="in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year"/>
  <result pre="analysis from RESONATE: Up to six years of follow-up on" exact="ibrutinib" post="in patients with previously treated chronic lymphocytic leukemia or"/>
  <result pre="Am J Hematol.2019;94:1353â€&quot;1363.31512258 54.BurgerJABarrPMRobakTet al.Long-term efficacy and safety of first-line" exact="ibrutinib" post="treatment for patients with CLL/SLL: 5 years of follow-up"/>
  <result pre="phase 3 trial. Lancet.2020;395:1278â€&quot;1291.32305093 57.FlinnIWHillmenPMontilloMet al.The phase 3 DUO trial:" exact="duvelisib" post="vs ofatumumab in relapsed and refractory CLL/SLL. Blood.2018;132:2446â€&quot;2455.30287523 58.FischerKAl-SawafOBahloJet"/>
  <result pre="lymphocytic leukemia. Blood Cancer J.2018;8:10.29339727 79.DavidsMSHallekMWierdaWet al.Comprehensive safety analysis of" exact="venetoclax" post="monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin"/>
  <result pre="treated with ibrutinib. Blood.2015;126:2213â€&quot;2219.26337493 81.VarugheseTTaurYCohenNet al.Serious infections in patients receiving" exact="ibrutinib" post="for treatment of lymphoid cancer. Clin Infect Dis.2018;67:687â€&quot;692.29509845 82.RogersKAMousaLZhaoQet"/>
  <result pre="cancer. Clin Infect Dis.2018;67:687â€&quot;692.29509845 82.RogersKAMousaLZhaoQet al.Incidence of opportunistic infections during" exact="ibrutinib" post="treatment for B-cell malignancies. Leukemia.2019;33:2527â€&quot;2530.31086260 83.de WeerdtIHoflandTde BoerRet al.Distinct"/>
  <result pre="node and peripheral blood of CLL patients is reshaped during" exact="venetoclax" post="treatment. Blood Adv.2019;3:2642â€&quot;2652.31506282 84.LongMBeckwithKDoPet al.Ibrutinib treatment improves T cell"/>
  <result pre="patients with chronic lymphocytic leukemia. J Immunol.2017;198:1740â€&quot;1747.28077600 86.TreonSPCastilloJSkarbnikAPet al.The BTK-inhibitor" exact="ibrutinib" post="may protect against pulmonary injury in COVID-19 infected patients."/>
  <result pre="chronic lymphocytic leukemia. N Engl J Med.2019;381:432â€&quot;443.31365801 89.Oâ€™BrienSMByrdJCHillmenPet al.Outcomes with" exact="ibrutinib" post="by line of therapy and post-ibrutinib discontinuation in patients"/>
  <result pre="90.ParikhSAAchenbachSJCallTGet al.The impact of dose modification and temporary interruption of" exact="ibrutinib" post="on outcomes of chronic lymphocytic leukemia patients in routine"/>
  <result pre="in routine clinical practice. Cancer Med.2020;9:3390â€&quot;3399.32187452 91.DaveNGopalakrishnanSMensingSet al.Model-informed dosing of" exact="venetoclax" post="in healthy subjects: an exposure-response analysis. Clin Transl Sci.2019;12:625â€&quot;632.31268229"/>
  <result pre="24, 2020. 10.1016/S2666-5247(20)30009-4. 114.HampelPJDingWCallTGet al.Rapid disease progression following discontinuation of" exact="ibrutinib" post="in patients with chronic lymphocytic leukemia treated in routine"/>
 </snippets>
</snippetsTree>
